Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 31Squamous Cell Carcinoma of Head and Neck 21Carcinoma, Non-Small-Cell Lung 20Neoplasms 18Breast Neoplasms 18Glioblastoma 17Esophageal Squamous Cell Carcinoma 16Rectal Neoplasms 15Lung Neoplasms 15Esophageal Neoplasms 15Head and Neck Neoplasms 12Uterine Cervical Neoplasms 11Neoplasm Metastasis 10Glioma 10Nasopharyngeal Carcinoma 8Stomach Neoplasms 7Radiation Injuries 7Oropharyngeal Neoplasms 7Brain Neoplasms 7Hyperthermia 6Carcinoma, Hepatocellular 6Astrocytoma 6Urinary Bladder Neoplasms 5Small Cell Lung Carcinoma 5Sarcoma 5Oligodendroglioma 5Colorectal Neoplasms 5Carcinoma, Renal Cell 5Triple Negative Breast Neoplasms 4Pancreatic Neoplasms 4

Interventions

atezolizumab 2lipoarabinomannan 1Specimen Handling 1Radiotherapy 1Radiation 1Magnetic Resonance Spectroscopy 1Lamivudine 1Etoposide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Extensive Stage Lung Small Cell Carcinoma × Radiotherapy × Clear all
NCT04402788 2026-06-02

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
138 enrolled

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡